MLH1 Hypermethylation Analysis, Tumor
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
As an adjunct to HNPCC / Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Screen, when colon or endometrial tumor demonstrates microsatellite instability (MSI-H) and loss of MLH1 protein expression, to help distinguish a somatic versus germline event prior to performing expensive germline testing
As an adjunct to negative MLH1 germline testing in cases where colon or endometrial tumor demonstrates MSI-H and loss of MLH1 protein expression
Note: Mayo's preferred screening test (MLBRF / MLH1 Hypermethylation and BRAF Mutation Analyses) includes both MLH1 promoter hypermethylation and BRAF V600E testing. Please note that test can only be performed on colon tumors.
Additional Tests Lists test(s) that are always performed, at an additional charge, with the initial test(s)
|Test ID||Reporting Name||Available Separately||Always Performed|
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
When this test is ordered, slide review will always be performed at an additional charge.
See Hereditary Nonpolyposis Colorectal Cancer Testing Algorithm in Special Instructions.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Polymerase Chain Reaction (PCR) Analysis
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
MLH1 Hypermethylation Analys, Tumor